Call (415) 636-9700 Mon–Fri 8a–8p · Sat 9a–5p

How to Get Prior Authorization for TMS in California: A Step-by-Step Patient Guide

TMS Therapy · Hayward, CA

The clinical case for TMS is straightforward when you meet the criteria. The administrative case — getting your insurance to actually pay for it — is where most patients get stuck. Prior authorization for TMS in California has a relatively predictable structure across major commercial plans, but every plan has nuances, and a sloppy submission can delay treatment by weeks.

This piece is the practical version. What insurance plans typically require, what your documentation needs to show, what to do if you’re denied, and the California Mental Health Parity Act protections that apply.

Exxceed Wellness · Hayward, CA

The clinical case for TMS is the easy part. The administrative case is where most California patients get stuck.

A board-certified psychiatric specialist (and attorney) walks through what insurers require, what documentation needs to show, and how the California Mental Health Parity Act protects your appeal.
Nefretiri Abat, JD, PMHNP-BCexxceedwellness.com

What every California commercial plan typically requires

The core criteria for TMS coverage across most major California insurers (Anthem Blue Cross, Blue Shield of California, Aetna, Cigna, UnitedHealthcare, Kaiser Permanente when applicable) are remarkably consistent. To approve TMS for major depressive disorder, plans typically require documentation that you meet all four of the following:

1. DSM-5 diagnosis of major depressive disorder, either single episode or recurrent, of at least moderate severity. Your psychiatric provider documents this with a current MDD ICD-10 code (F33.x for recurrent, F32.x for single episode) and a structured severity measure (PHQ-9 ≥ 15 or equivalent on MADRS or HRSD).[1]

2. Failure of at least two antidepressant trials in the current episode, at adequate dose for at least 6 weeks each. “Failed” means either no significant response (≤ 25% improvement in symptoms) or intolerable side effects requiring discontinuation. The two trials usually need to be from different classes — for example, an SSRI plus an SNRI, or an SSRI plus bupropion. Documentation needs specific drug names, dates, doses, and reasons for discontinuation.[2]

3. Failure of or contraindication to evidence-based psychotherapy. Most plans require documentation that you have either completed an adequate trial of CBT, interpersonal therapy, or behavioral activation without sufficient response, OR that psychotherapy is contraindicated or unavailable in your geography. Some plans waive this if you have severe symptoms or active suicidality.[2]

4. No absolute contraindication to TMS. Personal history of seizure disorder (relative contraindication, not absolute), ferromagnetic implants near the head (cochlear implants, certain dental hardware, aneurysm clips), cardiac pacemakers, or implanted medication pumps. Pregnancy is a separate consideration that may require additional review.[3]

What your medication trial documentation needs to show

This is the single most common point of failure in TMS prior-auth submissions. Insurers reject submissions where the trial documentation is vague. To meet the standard, each of your two failed trials should be documented with:

Specific medication name (e.g., sertraline, not “an SSRI”). Start date and end date. Maximum dose reached and how long you stayed at that dose (must be at least 4 weeks at the therapeutic dose, ideally 6+ weeks). Reason for discontinuation — either inadequate response (with specific symptom scores, ideally), intolerable side effects (specified), or contraindication that developed. Prescriber’s name and clinic.

If your prior medication trials are scattered across multiple providers and the records are incomplete, the most common workaround is for your current psychiatric provider to document the history based on patient report, pharmacy records, and any chart notes available. Pharmacy fill records (available from your pharmacy or your insurance’s claims database) are often the most reliable source for dose and duration.

California-specific protection: SB 855 / The Mental Health Parity Act

California law requires commercial insurers to cover medically necessary mental health treatment with parity.

California Senate Bill 855 (effective January 1, 2021) requires commercial health plans regulated by the Department of Managed Health Care (DMHC) or the Department of Insurance (CDI) to cover the diagnosis and medically necessary treatment of all mental health and substance use disorders under the same terms and conditions as physical health conditions. This includes TMS for treatment-resistant depression when the medical necessity criteria are met. If your insurer denies TMS coverage despite meeting the four core criteria above, the denial is appealable on parity grounds.[4] The DMHC Help Center (1-888-466-2219) handles consumer complaints against managed care plans; the CDI consumer hotline (1-800-927-4357) handles complaints against fully-insured plans. The California Mental Health Services Oversight and Accountability Commission may also be a resource.

The submission itself

Your TMS clinic’s prior-authorization specialist or billing team will typically prepare and submit the request. From your side, what helps:

Provide complete medication history as far back as you can — even trials from years ago in the same episode count if you can document them. Bring pharmacy fill records.

Confirm your diagnosis is documented as MDD specifically, not just “depression NOS” or “adjustment disorder with depressed mood.” Insurers look for F32.x or F33.x ICD-10 codes.

Get a current PHQ-9 or MADRS score from your psychiatric provider. Most insurers expect a score of ≥ 15 on PHQ-9 (moderately severe to severe range).

If you’ve tried psychotherapy, document the modality (CBT, IPT, BA), duration, frequency, and outcome.

If you have a recent prior denial from the same insurer for any mental health treatment, share it — it’s relevant context.

Typical timeline

Once your TMS clinic submits a complete prior-auth packet, most California commercial plans respond within 5 business days for standard requests. Urgent requests (active suicidality, severe functional impairment) can be expedited to 72 hours under California regulation. If the plan asks for additional information, that pauses the clock until the information is provided.

If approved, the authorization usually covers a specific number of sessions (typically 30 acute + 6 taper, sometimes 36 acute only) within a specific time window (usually 6 months from the approval date). Verify both numbers in the approval letter.

The four prior-auth criteria

What every California commercial plan typically requires.

  • DSM-5 MDD diagnosis — Recurrent (F33.x) or single episode (F32.x), with PHQ-9 ≥ 15 or equivalent on MADRS/HRSD.
  • Two failed antidepressant trials — Different classes, each at adequate dose for ≥ 6 weeks, with specific drug names, dates, doses, and reasons for discontinuation documented.
  • Psychotherapy trial or contraindication — Documentation of CBT/IPT/BA trial without sufficient response, OR documented contraindication or unavailability.
  • No absolute TMS contraindication — Ferromagnetic implants, pacemaker, recent seizure (relative). Screened by your TMS clinic.
Source: McClintock NNDC consensus · CMS LCD · APA Practice Guidelinesexxceedwellness.com

If you’re denied: the appeal process

Denials are common on first submission, especially when the documentation has gaps. Most denials are reversible on appeal if the underlying criteria are met. The typical sequence:

Read the denial letter carefully. California law requires the insurer to state the specific reason for denial in writing. The most common reasons are: insufficient documentation of failed antidepressant trials, missing documentation of psychotherapy trial, diagnosis not coded specifically enough, or medical necessity criteria not met as stated.

Request a copy of the medical necessity criteria the plan used. California’s SB 855 requires plans to use generally accepted standards of professional mental health practice — typically the APA Practice Guidelines for the Treatment of Patients with Major Depressive Disorder, the NNDC consensus for TMS, or the CMS Local Coverage Determination for TMS. Match your documentation against the specific criteria.[1][2]

Submit an internal appeal with corrected/expanded documentation. Your TMS clinic’s billing team will usually handle this. The appeal should specifically address each reason cited in the denial.

If the internal appeal is denied, request an Independent Medical Review (IMR). California provides free, binding IMR through the DMHC or CDI depending on which agency regulates your plan. IMR is conducted by independent specialist physicians and the decision is binding on the insurer. IMRs for TMS denials have a meaningful approval rate when the underlying criteria are met.

If applicable, raise the parity argument. If your insurer covers comparable medical procedures (e.g., physical-medicine interventions for chronic pain) under less restrictive criteria than they apply to TMS for depression, you may have a parity violation. Document this and include it in the IMR submission.[4]

If you’re denied — the appeal path

The four-step California appeal sequence.

1

Read the denial letter

California law requires specific written reasons. Most common: insufficient med-trial documentation, missing psychotherapy trial, or diagnosis not coded specifically.

2

Get the medical necessity criteria

Plans must use generally accepted standards (APA, NNDC consensus, CMS LCD). Match your documentation against the specific criteria cited.

3

Internal appeal

Your TMS clinic’s billing team submits expanded documentation addressing each denial reason. Most denials with valid underlying criteria are reversible at this stage.

4

Independent Medical Review (IMR)

Free, binding review through DMHC (1-888-466-2219) or CDI (1-800-927-4357). Specialist physicians review the case. Decision is binding on the insurer.

Save · Reference if deniedexxceedwellness.com

What to ask your TMS clinic before you start

“Have you billed my insurance for TMS before?” Clinics with experience billing your specific plan are much faster at getting clean approvals.

“What documentation do I need to bring or send?” Get a specific list, not generalities.

“How long does prior auth typically take for my insurer?” Most clinics know the typical turnaround for the major California plans.

“What is your appeal success rate if we’re initially denied?” A good answer should reference IMR rates and specific reasons for prior denials.

“What is your cash-pay price if I have to self-fund?” Some clinics offer significant discounts off the chargemaster rate for cash-pay patients.

The bottom line

Most California commercial plans cover TMS for treatment-resistant depression when patients meet four criteria: MDD diagnosis, two failed antidepressant trials at adequate dose and duration, failure of (or contraindication to) psychotherapy, and no absolute TMS contraindication. The documentation has to be specific — vague trial history is the most common cause of first-submission denial.

If you’re denied, the California Mental Health Parity Act (SB 855) provides legal grounds for appeal, and the state’s Independent Medical Review process is binding on insurers. Most denials with valid underlying criteria can be reversed on appeal.[4]

If you’re in Hayward or the East Bay and you want to talk through whether your case meets the criteria and how to assemble the documentation, that’s what a consultation is for.

Need help with the documentation?

A practice that knows both the clinical and legal side.

Nef holds both a PMHNP-BC clinical license and a California JD. Exxceed Wellness handles TMS prior-auth submissions in Hayward, CA with detailed documentation, parity-grounded appeals when denied, and IMR support when needed.

Schedule a consultation →

Nefretiri Abat, JD, PMHNP-BC
Founder, Exxceed Wellness · Hayward, CA
Exxceed Wellness · 2026exxceedwellness.com

References

  1. Sforzini L, Worrell C, Kose M, et al. A Delphi-method-based consensus guideline for the definition of treatment-resistant depression for clinical trials. Mol Psychiatry. 2022;27(3):1286-1299. PMID: 34907394. doi:10.1038/s41380-021-01381-x.
  2. McClintock SM, Reti IM, Carpenter LL, et al. Consensus recommendations for the clinical application of repetitive transcranial magnetic stimulation (rTMS) in the treatment of depression. J Clin Psychiatry. 2018;79(1):16cs10905. PMID: 28541649. doi:10.4088/JCP.16cs10905.
  3. Rossi S, Antal A, Bestmann S, et al. Safety and recommendations for TMS use in healthy subjects and patient populations, with updates on training, ethical and regulatory issues: Expert Guidelines. Clin Neurophysiol. 2021;132(1):269-306. PMID: 33243615. doi:10.1016/j.clinph.2020.10.003.
  4. California Department of Managed Health Care. Senate Bill 855 (2020) Mental Health Parity Implementation. Effective January 1, 2021. dmhc.ca.gov.
  5. Lefaucheur JP, Aleman A, Baeken C, et al. Evidence-based guidelines on the therapeutic use of repetitive transcranial magnetic stimulation (rTMS): an update (2014–2018). Clin Neurophysiol. 2020;131(2):474-528. PMID: 31901449. doi:10.1016/j.clinph.2019.11.002.
  6. Rush AJ, Trivedi MH, Wisniewski SR, et al. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. Am J Psychiatry. 2006;163(11):1905-1917. PMID: 17074942. doi:10.1176/ajp.2006.163.11.1905.

Comments are closed